[Federal Register: November 6, 2006 (Volume 71, Number 214)]
[Notices]
[Page 65019-65021]
[DOCID:fr06no06-70]

-----------------------------------------------------------------------

SECURITIES AND EXCHANGE COMMISSION

[Release No. 34-54675; File No. SR-NYSE-2006-96]

Self-Regulatory Organizations; New York Stock Exchange LLC;
Notice of Filing and Immediate Effectiveness of Proposed Rule Change
Relating to a Request to Extend the Pilot Operating During the
Exchange's Implementation of NYSE Hybrid Market Phase 3 Until November
30, 2006

October 31, 2006.
    Pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934
(``Act'') \1\ and Rule 19b-4 thereunder,\2\ notice is hereby given that
on October 26, 2006, the New York Stock Exchange LLC (``NYSE'' or
``Exchange'') filed with the Securities and Exchange Commission
(``Commission'') the proposed rule change as described in Items I and
II below, which Items have been prepared by the Exchange. NYSE filed
the proposed rule change pursuant to Section 19(b)(3)(A) of the Act \3\
and

Rule 19b-4(f)(6) thereunder,\4\ which renders the proposal effective
upon filing with the Commission. The Commission is publishing this
notice to solicit comments on the proposed rule change from interested
persons.
---------------------------------------------------------------------------

    \1\ 15 U.S.C. 78s(b)(1).
    \2\ 17 CFR 240.19b-4.
    \3\ 15 U.S.C. 78s(b)(3)(A).
    \4\ 17 CFR 240.19b-4(f)(6).
---------------------------------------------------------------------------

I. Self-Regulatory Organization's Statement of the Terms of Substance
of the Proposed Rule Change

    NYSE proposes to extend the pilot (``Pilot'') \5\ which put into
operation certain rule changes pending before the Commission to
coincide with the Exchange's implementation of NYSE HYBRID MARKET\SM\
(``Hybrid Market'') \6\ Phase 3.
---------------------------------------------------------------------------

    \5\ See Securities Exchange Act Release Nos. 54578 (October 5,
2006), 71 FR 60216 (October 12, 2006) and 54610 (October 16, 2006),
71 FR 62142 (October 23, 2006).
    \6\ The Hybrid Market was approved on March 22, 2006. See
Securities Exchange Act Release No. 53539 (March 22, 2006), 71 FR
16353 (March 31, 2006).
---------------------------------------------------------------------------

II. Self-Regulatory Organization's Statement of the Purpose of, and
Statutory Basis for, the Proposed Rule Change

    In its filing with the Commission, the Exchange included statements
concerning the purpose of and basis for the proposed rule change and
discussed any comments it received on the proposed rule change. The
text of these statements may be examined at the places specified in
Item IV below. The Exchange has prepared summaries, set forth in
Sections A, B, and C below, of the most significant aspects of such
statements.

A. Self-Regulatory Organization's Statement of the Purpose of, and
Statutory Basis for, the Proposed Rule Change

1. Purpose
    On October 5, 2006, the Commission approved the Pilot to, among
other things, put into operation certain proposed modifications to
Exchange Rules that are currently pending \7\ before the Commission to
coincide with the Exchange's implementation of the Hybrid Market Phase
3. The Pilot commenced on October 6, 2006 \8\ and is scheduled to
terminate on the close of business October 31, 2006.
---------------------------------------------------------------------------

    \7\ See, Securities Exchange Act Release Nos. 54520 (September
27, 2006), 71 FR 57590 (September 29, 2006) (proposing to amend
several Exchange Rules to clarify certain definitions and systemic
processes (``Omnibus Filing'')); 54504 (September 26, 2006), 71 FR
57011 (September 28, 2006) (proposing to amend the specialist
stabilization requirements set forth in Exchange Rule 104.10
(``Stabilization Filing'')); and SR-NYSE-2006-73 (filed on September
13, 2006) and Amendment No. 1 thereto (filed on October 13, 2006)
(proposing to amend Exchange Rule 127 which governs the execution of
a block cross transaction at a price outside the prevailing NYSE
quotation (``Block Cross Filing'')).
    \8\ The changes related to stop orders and stop limit orders
proposed in the Omnibus Filing were implemented on October 16, 2006
in order to give customers and member organizations sufficient time
to make any changes necessary as a result of the elimination of stop
limit orders.
---------------------------------------------------------------------------

    The Exchange proposes to extend the Pilot through November 30, 2006
or the earlier of Commission approval of the Omnibus Filing,
Stabilization Filing and the Block Cross Filing while the Commission
continues to review the aforementioned pending filings. The approval of
any one of the pending filings terminates the operation of the rules
associated with the approved filing from the Pilot. The Pilot shall not
terminate in its entirety unless and until all pending filings are
approved or November 30, 2006.
    An extension of the Pilot will allow the Exchange to continue to
operate the Hybrid Market Phase 3 and commence implementation of Hybrid
Market Phase 4 in a timely manner. The Exchange believes that an
extension of the Pilot will also enable the Exchange to be fully
Regulation NMS \9\-compliant by February 5, 2007 date and comply with
its obligations under the proposed NMS Linkage Plan.\10\
---------------------------------------------------------------------------

    \9\ See Securities Exchange Act Release No. 51808 (June 9,
2005), 70 FR 37496 (June 29, 2005).
    \10\ A ``Plan for the Purpose of Creating and Operating an
Intermarket Communications Linkage Pursuant to Section 11A(a)(3)(B)
of the Securities Exchange Act of 1934'' to facilitate trades
between different market centers. See Securities Exchange Act
Release No. 54551 (September 29, 2006), 71 FR 59148 (October 6,
2006). The Commission published notice of the NMS Linkage Plan on
July 28, 2006. See Securities Exchange Act Release No. 54239 (July
28, 2006), 71 FR 44328 (August 4, 2006).
---------------------------------------------------------------------------

    The Exchange further believes that extending the Pilot will allow
it to continue identifying and addressing any system problems. The
Exchange will continue to identify and incorporate beneficial system
changes that become apparent as a result of usage in real time and
under real market conditions.
    An extension of the Pilot will further the Exchange's ability to
have real time user interface which is proving very useful to the
Exchange. Moreover, by extending the Pilot, current users will continue
gaining the essential practical experience with the new systems and
processes in a well-modulated way, in real time and under real market
conditions that cannot be completely replicated in the mock-trading
environment.
    The Exchange is currently in the process of phasing in the
securities operating under the Pilot. As expected, the Pilot is
operating with minimal problems and the benefits as described above are
proving invaluable. Therefore, the Exchange believes it is appropriate
to extend the Pilot through November 30, 2006 or the earlier of
Commission approval of the pending filings as described above.
2. Statutory Basis
    The Exchange believes that the proposed rule change is consistent
with Section 6(b) of the Act \11\ in general, and furthers the
objectives of Section 6(b)(5) of the Act \12\ in particular, in that it
is designed to promote just and equitable principles of trade, to
remove impediments to and perfect the mechanism of a free and open
market and a national market system, and, in general, to protect
investors and the public interest. The Exchange believes that the
proposed rule change is also designed to support the principles of
Section 11A(a)(1) of the Act \13\ in that it seeks to assure
economically efficient execution of securities transactions.
---------------------------------------------------------------------------

    \11\ 15 U.S.C. 78f.
    \12\ 15 U.S.C. 78f(b)(5).
    \13\ 15 U.S.C. 78k-1(a)(1).
---------------------------------------------------------------------------

B. Self-Regulatory Organization's Statement on Burden on Competition

    The Exchange does not believe that the proposed rule change will
impose any burden on competition that is not necessary or appropriate
in furtherance of the purposes of the Act.

C. Self-Regulatory Organization's Statement on Comments on the Proposed
Rule Change Received From Members, Participants or Others

    The Exchange has neither solicited nor received written comments on
the proposed rule change.

III. Date of Effectiveness of the Proposed Rule Change and Timing for
Commission Action

    Because the foregoing proposed rule change does not significantly
affect the protection of investors or the public interest; does not
impose any significant burden on competition; and by its terms, does
not become operative for 30 days from the date on which it was filed,
or such shorter time as the Commission may designate if consistent with
the protection of investors and the public interest, it has become
effective pursuant to Section 19(b)(3)(A) of the Act \14\ and Rule 19b-
4(f)(6) thereunder.\15\
---------------------------------------------------------------------------

    \14\ 15 U.S.C. 78s(b)(3)(A).
    \15\ 17 CFR 240.19b-4(f)(6).
---------------------------------------------------------------------------

    A proposed rule change filed under Rule 19b-4(f)(6) normally may
not become operative prior to 30 days after the date of filing.
However, Rule 19b-

4(f)(6)(iii) \16\ permits the Commission to designate a shorter time if
such action is consistent with the protection of investors and the
public interest. The Exchange has requested that the Commission waive
the five-day pre-filing notice requirement and the 30-day operative
delay and designate the proposed rule change immediately operative upon
filing. The Commission believes that waiver of the five-day pre-filing
notice requirement and the 30-day operative delay is consistent with
the protection of investors and the public interest because it would
allow the Pilot to continue without interruption. Accordingly, the
Commission designates the proposal to be effective and operative upon
filing with the Commission on a pilot basis until November 30,
2006.\17\
---------------------------------------------------------------------------

    \16\ 17 CFR 240.19b-4(f)(6)(iii).
    \17\ For purposes only of waiving the 30-day operative delay,
the Commission has considered the proposed rule's impact on
efficiency, competition, and capital formation. 15 U.S.C. 78c(f).
---------------------------------------------------------------------------

    At any time within 60 days of the filing of the proposed rule
change, the Commission may summarily abrogate such rule change if it
appears to the Commission that such action is necessary or appropriate
in the public interest, for the protection of investors, or otherwise
in furtherance of the purposes of the Act.

IV. Solicitation of Comments

    Interested persons are invited to submit written data, views and
arguments concerning the foregoing, including whether the proposed rule
change is consistent with the Act. Comments may be submitted by any of
the following methods:

Electronic Comments

     Use the Commission's Internet comment form (http://www.sec.gov/rules/sro.shtml.
); or     Send an e-mail to<EMAIL_ADDRESS>Please include

File Number SR-NYSE-2006-96 on the subject line.

Paper Comments

     Send paper comments in triplicate to Nancy M. Morris,
Secretary, Securities and Exchange Commission, 100 F Street, NE.,
Washington, DC 20549-1090.

    All submissions should refer to File Number SR-NYSE-2006-96. This
file number should be included on the subject line if e-mail is used.
To help the Commission process and review your comments more
efficiently, please use only one method. The Commission will post all
comments on the Commission's Internet Web site (http://www.sec.gov/rules/sro.shtml
). Copies of the submission, all subsequent amendments,

all written statements with respect to the proposed rule change that
are filed with the Commission, and all written communications relating
to the proposed rule change between the Commission and any person,
other than those that may be withheld from the public in accordance
with the provisions of 5 U.S.C. 552, will be available for inspection
and copying in the Commission's Public Reference Room. Copies of such
filing also will be available for inspection and copying at the
principal office of the Exchange. All comments received will be posted
without change; the Commission does not edit personal identifying
information from submissions. You should submit only information that
you wish to make available publicly. All submissions should refer to
File Number SR-NYSE-2006-96 and should be submitted on or before
November 27, 2006.

    For the Commission, by the Division of Market Regulation,
pursuant to delegated authority.\18\
---------------------------------------------------------------------------

    \18\ 17 CFR 200.30-3(a)(12).
---------------------------------------------------------------------------

Nancy M. Morris,
Secretary.
 [FR Doc. E6-18634 Filed 11-3-06; 8:45 am]

BILLING CODE 8011-01-P


[Federal Register Volume 85, Number 173 (Friday, September 4, 2020)]
[Rules and Regulations]
[Pages 55193-55196]
[FR Doc No: 2020-17791]

=======================================================================
-----------------------------------------------------------------------

ENVIRONMENTAL PROTECTION AGENCY

40 CFR Part 180

[EPA-HQ-OPP-2019-0273; FRL-10012-18]

Pydiflumetofen; Pesticide Tolerance

AGENCY: Environmental Protection Agency (EPA).

ACTION: Final rule.

-----------------------------------------------------------------------

SUMMARY: This regulation establishes tolerances for the inadvertent
residues of pydiflumetofen in or on animal feed, nongrass, group 18,
hay; grass, forage, fodder and hay, group 17, except straw; and grass,
forage, fodder and hay, group 17, straw. Syngenta Crop Protection, LLC
requested this tolerance under the Federal Food, Drug, and Cosmetic Act
(FFDCA).

DATES: This regulation is effective September 4, 2020. Objections and
requests for hearings must be received on or before November 3, 2020,
and must be filed in accordance with the instructions provided in 40
CFR part 178 (see also Unit I.C. of the SUPPLEMENTARY INFORMATION).

ADDRESSES: The docket for this action, identified by docket
identification (ID) number EPA-HQ-OPP-2019-0273, is available at http://www.regulations.gov or at the Office of Pesticide Programs Regulatory
Public Docket (OPP Docket) in the Environmental Protection Agency
Docket Center (EPA/DC), West William Jefferson Clinton Bldg., Rm. 3334,
1301 Constitution Ave. NW, Washington, DC 20460-0001. The Public
Reading Room is open from 8:30 a.m. to 4:30 p.m., Monday through
Friday, excluding legal holidays. The telephone number for the Public
Reading Room is<PHONE_NUMBER>, and the telephone number for the OPP
Docket is<PHONE_NUMBER>.
    Due to the public health concerns related to COVID-19, the EPA
Docket Center (EPA/DC) and Reading Room is closed to visitors with
limited exceptions. The staff continues to provide remote customer
service via email, phone, and webform. For the latest status
information on EPA/DC services and docket access, visit https://www.epa.gov/dockets.

FOR FURTHER INFORMATION CONTACT: Marietta Echeverria, Registration
Division (7505P), Office of Pesticide Programs, Environmental
Protection Agency, 1200 Pennsylvania Ave. NW, Washington, DC 20460-
0001; main telephone number:<PHONE_NUMBER>; email address:
<EMAIL_ADDRESS>
SUPPLEMENTARY INFORMATION:

I. General Information

A. Does this action apply to me?

    You may be potentially affected by this action if you are an
agricultural producer, food manufacturer, or pesticide manufacturer.
The following list of North American Industrial Classification System
(NAICS) codes is not intended to be exhaustive, but rather provides a
guide to help readers determine whether this document applies to them.
Potentially affected entities may include:
     Crop production (NAICS code 111).
     Animal production (NAICS code 112).
     Food manufacturing (NAICS code 311).
     Pesticide manufacturing (NAICS code 32532).

B. How can I get electronic access to other related information?

    You may access a frequently updated electronic version of EPA's
tolerance regulations at 40 CFR part 180 through the Government
Publishing Office's e-CFR site at http://www.ecfr.gov/cgi-bin/text-idx?&c=ecfr&tpl=/ecfrbrowse/Title40/40tab_02.tpl.

C. How can I file an objection or hearing request?

    Under FFDCA section 408(g), 21 U.S.C. 346a, any person may file an
objection to any aspect of this regulation and may also request a
hearing on those objections. You must file your objection or request a
hearing on this regulation in accordance with the instructions provided
in 40 CFR part 178. To ensure proper receipt by EPA, you must identify
docket ID number EPA-HQ-OPP-2019-0273 in the subject line on the first
page of your submission. All objections and requests for a hearing must
be in writing and must be received by the Hearing Clerk on or before
November 3, 2020. Addresses for mail and hand delivery of objections
and

hearing requests are provided in 40 CFR 178.25(b).
    In addition to filing an objection or hearing request with the
Hearing Clerk as described in 40 CFR part 178, please submit a copy of
the filing (excluding any Confidential Business Information (CBI)) for
inclusion in the public docket. Information not marked confidential
pursuant to 40 CFR part 2 may be disclosed publicly by EPA without
prior notice. Submit the non-CBI copy of your objection or hearing
request, identified by docket ID number EPA-HQ-OPP-2019-0273, by one of
the following methods:
     Federal eRulemaking Portal: http://www.regulations.gov.
Follow the online instructions for submitting comments. Do not submit
electronically any information you consider to be CBI or other
information whose disclosure is restricted by statute.
     Mail: OPP Docket, Environmental Protection Agency Docket
Center (EPA/DC), (28221T), 1200 Pennsylvania Ave. NW, Washington, DC
20460-0001.
     Hand Delivery: To make special arrangements for hand
delivery or delivery of boxed information, please follow the
instructions at http://www.epa.gov/dockets/contacts.html.
    Additional instructions on commenting or visiting the docket, along
with more information about dockets generally, is available at http://www.epa.gov/dockets.

II. Summary of Petitioned-For Tolerance

    In the Federal Register of June 7, 2019 (84 FR 26630) (FRL-9993-
93), EPA issued a document pursuant to FFDCA section 408(d)(3), 21
U.S.C. 346a(d)(3), announcing the filing of a pesticide petition (PP
9F8744) by Syngenta Crop Protection, LLC., P.O. Box 18300, Greensboro,
NC 27419. The petition requested that 40 CFR 180.699 be amended by
establishing tolerances for inadvertent residues of the fungicide,
pydiflumetofen (3-(difluoromethyl)-N-methoxy-1-methyl-N-[1-methyl-2-
(2,4,6 trichlorophenyl)ethyl]-1H-pyrazole-4-carboxamide) in or on rice,
grain at 0.01 parts per million (ppm); non-grass animal feed (Crop
Group 18), forage at 0.01 ppm; non-grass animal feed (Crop Group 18),
hay at 0.03 ppm; grasses, forage at 0.15 ppm; grasses, hay at 0.50 ppm;
grasses, straw at 0.04 ppm. That document referenced a summary of the
petition prepared by Syngenta Crop Protection, LLC, the registrant,
which is available in the docket, http://www.regulations.gov. There
were no comments received in response to the notice of filing. Based
upon review of the data supporting the petition, EPA is establishing
tolerances that vary slightly from what the petitioner requested, by
using altered commodity definitions to reflect the Agency's preferred
terminology and adjusted tolerance levels for several commodities. In
addition, EPA is not establishing tolerances for residues of
pydiflumetofen in or on rice, grain and non-grass animal feed (crop
group 18), forage. The reasons for these changes are explained in Unit
IV.D.

III. Aggregate Risk Assessment and Determination of Safety

    Section 408(b)(2)(A)(i) of FFDCA allows EPA to establish a
tolerance (the legal limit for a pesticide chemical residue in or on a
food) only if EPA determines that the tolerance is ``safe.'' Section
408(b)(2)(A)(ii) of FFDCA defines ``safe'' to mean that ``there is a
reasonable certainty that no harm will result from aggregate exposure
to the pesticide chemical residue, including all anticipated dietary
exposures and all other exposures for which there is reliable
information.'' This includes exposure through drinking water and in
residential settings but does not include occupational exposure.
Section 408(b)(2)(C) of FFDCA requires EPA to give special
consideration to exposure of infants and children to the pesticide
chemical residue in establishing a tolerance and to ``ensure that there
is a reasonable certainty that no harm will result to infants and
children from aggregate exposure to the pesticide chemical residue. . .
.''
    Consistent with FFDCA section 408(b)(2)(D), and the factors
specified in FFDCA section 408(b)(2)(D), EPA has reviewed the available
scientific data and other relevant information in support of this
action. EPA has sufficient data to assess the hazards of and to make a
determination on aggregate exposure for pydiflumetofen including
exposure resulting from the tolerances established by this action.
EPA's assessment of exposures and risks associated with pydiflumetofen
follows.
    On August 12, 2019, EPA published in the Federal Register a final
rule establishing a tolerance for residues of the fungicide
pydiflumetofen in or on various commodities. See (84 FR 39761) (FRL-
9997-09). EPA is incorporating by reference the aspects of that
rulemaking that remain the same for this rulemaking: The toxicological
profile and points of departure/levels of concern; the determination
for reducing the children's safety factor and conclusions about
cumulative risk. The Agency conducted an updated risk assessment to
evaluate exposure to residues of pydiflumetofen from the reduced plant-
back intervals on rice, grass grown for seed, non-grass animal feed
crop group 18, and tobacco and concluded that the new use patterns
would not impact previously assessed drinking water, dietary (food and
drinking water), or residential, exposures to humans from the reduced
plant-back intervals. Therefore, the Agency's conclusions of aggregate
risk remain unchanged from the August 12, 2019 rulemaking and are also
incorporated into this rulemaking.
    Further information about EPA's risk assessment and determination
of safety supporting the tolerances for inadvertent residues
established in the August 12, 2019 Federal Register action, as well as
the new pydiflumetofen tolerance can be found at http://www.regulations.gov in the document entitled, ``Pydiflumetofen. Human
Health Risk Assessment for New Foliar Uses on Berries, Low Growing,
Crop Subgroup 13-07G; Brassica Head and Stem Crop Group 5-16; Brassica
Leafy Greens Subgroup 4-16B; Bulb Vegetable Crop Subgroup 3-07A; Green
Onion Crop Subgroup 3-07B; Bushberry Crop Subgroup 13-07B; Citrus Fruit
Crop Group 10-10; Cottonseed Subgroup 20C; Edible-podded Legume
Vegetables Subgroup 6A; Succulent Shelled Pea and Bean Subgroup 6B;
Pome Fruit Crop Group 11-10; Root Vegetable Crop Subgroup 1A; Sorghum;
Stone Fruit Crop Subgroups 12-12A, 12-12B, and 12-12C; Sunflower
Subgroup 20B; Tree Nut Crop Group 14-12; Leaves of Root and Tuber
Vegetable Crop Group 2; and New Seed Treatment Uses on Rapeseed Crop
Subgroup 20A and Soybean; and Registration of a New Seed Treatment End-
Use Product,'' dated July 22, 2019, in docket ID EPA-HQ-OPP-2018-0688.
    Therefore, based on the risk assessments and information described
above, EPA concludes there is a reasonable certainty that no harm will
result to the general population, or to infants and children, from
aggregate exposure to pydiflumetofen residues. More detailed
information on the subject action to establish tolerances in or on
animal feed, nongrass, group 18, hay; grass, forage, fodder and hay,
group 17, except straw; and grass, forage, fodder and hay, group 17,
straw can be found in the document entitled, ``Pydiflumetofen. Human
Health Risk Assessment for Amended Registrations to Allow 30-Day
Minimum Plant-Back Interval (PBI) Restrictions for Rice, Grass Grown
for Seed, Non-Grass Animal Feed Crop Group 18, and Tobacco and Petition
for Inadvertent Tolerances in or on These Crops/Commodities.'' at
http://

www.regulations.gov, under docket ID number EPA-HQ-OPP-2019-0273.

IV. Other Considerations

A. Analytical Enforcement Methodology

    A multi-residue analytical method named Quick, Easy, Cheap,
Effective, Rugged, and Safe (QuEChERS) is adequate as the enforcement
method for plant commodities. QuEChERS as described in Eurofins
validation study S14-05402. The method may be requested from: Chief,
Analytical Chemistry Branch, Environmental Science Center, 701 Mapes
Rd., Ft. Meade, MD 20755-5350; telephone number:<PHONE_NUMBER>; email
address<EMAIL_ADDRESS>
B. International Residue Limits

    In making its tolerance decisions, EPA seeks to harmonize U.S.
tolerances with international standards whenever possible, consistent
with U.S. food safety standards and agricultural practices. EPA
considers the international maximum residue limits (MRLs) established
by the Codex Alimentarius Commission (Codex), as required by FFDCA
section 408(b)(4). The Codex Alimentarius is a joint United Nations
Food and Agriculture Organization/World Health Organization food
standards program, and it is recognized as an international food safety
standards-setting organization in trade agreements to which the United
States is a party. EPA may establish a tolerance that is different from
a Codex MRL; however, FFDCA section 408(b)(4) requires that EPA explain
the reasons for departing from the Codex level.
    The Codex has not established MRLs for pydiflumetofen in or on any
of the commodities under consideration.

C. Revisions to Petitioned-For Tolerances

    The requested tolerance for ``non-grass animal feed (Crop Group
18), hay'' was modified to read ``Animal feed, nongrass, group 18,
hay'' to be consistent with Agency naming practices. Requested
tolerances for ``grasses, forage,'' ``grasses, hay,'' and ``grasses,
straw'' were revised to read ``Grass, forage, fodder and hay, group 17,
except straw'' and ``Grass, forage, fodder and hay, group 17, straw''
respectively, to be more consistent with the Agency's preferred
vocabulary and because EPA considers group 17 to be inclusive of a
general request for tolerances on grasses.
    Tolerances for inadvertent residues of pydiflumetofen were
requested for non-grass animal feed (Crop Group 18), forage and rice,
grain; however, the Agency is not setting tolerances because residues
of pyflumetofen in field accumulation in rotational crop trials were
found at <0.01 ppm in or on these commodities, and the Agency does not
believe that tolerances are needed, in accordance with the Agency's
guidance (OPPTS Guideline 860.1900).
    The Agency is setting a tolerance in or on animal feed, nongrass,
group 18, hay, of 0.04 ppm rather than at 0.03 ppm as requested based
on clover hay data. The Agency is also setting a tolerance in or on
grass, forage, fodder and hay, group 17, except straw of 0.7 ppm based
on available data, which indicates that residues in or on grass forage
and hay are within 5x, but residues on straw are much lower.

V. Conclusion

    Therefore, tolerances are established for residues of
pydiflumetofen in or on animal feed, nongrass, group 18, hay; grass,
forage, fodder and hay, group 17, except straw; and grass, forage,
fodder and hay, group 17, straw.

VI. Statutory and Executive Order Reviews

    This action establishes tolerances under FFDCA section 408(d) in
response to a petition submitted to the Agency. The Office of
Management and Budget (OMB) has exempted these types of actions from
review under Executive Order 12866, entitled ``Regulatory Planning and
Review'' (58 FR 51735, October 4, 1993). Because this action has been
exempted from review under Executive Order 12866, this action is not
subject to Executive Order 13211, entitled ``Actions Concerning
Regulations That Significantly Affect Energy Supply, Distribution, or
Use'' (66 FR 28355, May 22, 2001) or Executive Order 13045, entitled
``Protection of Children from Environmental Health Risks and Safety
Risks'' (62 FR 19885, April 23, 1997), nor is it considered a
regulatory action under Executive Order 13771, entitled ``Reducing
Regulations and Controlling Regulatory Costs'' (82 FR 9339, February 3,
2017). This action does not contain any information collections subject
to OMB approval under the Paperwork Reduction Act (PRA) (44 U.S.C. 3501
et seq.), nor does it require any special considerations under
Executive Order 12898, entitled ``Federal Actions to Address
Environmental Justice in Minority Populations and Low-Income
Populations'' (59 FR 7629, February 16, 1994).
    Since tolerances and exemptions that are established on the basis
of a petition under FFDCA section 408(d), such as the tolerance for
inadvertent residues in this final rule, do not require the issuance of
a proposed rule, the requirements of the Regulatory Flexibility Act
(RFA) (5 U.S.C. 601 et seq.), do not apply.
    This action directly regulates growers, food processors, food
handlers, and food retailers, not States or Tribes, nor does this
action alter the relationships or distribution of power and
responsibilities established by Congress in the preemption provisions
of FFDCA section 408(n)(4). As such, the Agency has determined that
this action will not have a substantial direct effect on States or
Tribal Governments, on the relationship between the National Government
and the States or Tribal Governments, or on the distribution of power
and responsibilities among the various levels of government or between
the Federal Government and Indian Tribes. Thus, the Agency has
determined that Executive Order 13132, entitled ``Federalism'' (64 FR
43255, August 10, 1999) and Executive Order 13175, entitled
``Consultation and Coordination with Indian Tribal Governments'' (65 FR
67249, November 9, 2000) do not apply to this action. In addition, this
action does not impose any enforceable duty or contain any unfunded
mandate as described under Title II of the Unfunded Mandates Reform Act
(UMRA) (2 U.S.C. 1501 et seq.).
    This action does not involve any technical standards that would
require Agency consideration of voluntary consensus standards pursuant
to section 12(d) of the National Technology Transfer and Advancement
Act (NTTAA) (15 U.S.C. 272 note).

VII. Congressional Review Act

    Pursuant to the Congressional Review Act (5 U.S.C. 801 et seq.),
EPA will submit a report containing this rule and other required
information to the U.S. Senate, the U.S. House of Representatives, and
the Comptroller General of the United States prior to publication of
the rule in the Federal Register. This action is not a ``major rule''
as defined by 5 U.S.C. 804(2).

List of Subjects in 40 CFR Part 180

    Environmental protection, Administrative practice and procedure,
Agricultural commodities, Pesticides and pests, Reporting and
recordkeeping requirements.

    Dated: July 29, 2020.
Catherine Aubee,
Acting Director, Registration Division, Office of Pesticide Programs.

    Therefore, for the reasons stated in the preamble, EPA amends 40
CFR chapter I as follows:

PART 180--[AMENDED]

0
1. The authority citation for part 180 continues to read as follows:

    Authority: 21 U.S.C. 321(q), 346a and 371.

0
2. In Sec.  180.699, revise paragraph (d) to read as follows:

Sec.  180.699  Pydiflumetofen; tolerances for residues.

* * * * *
    (d) Indirect or inadvertent residues. Tolerances are established
for residues of pydiflumetofen, including its metabolites and
degradates, in or on the commodities in table 2 to this paragraph (d).
Compliance with the tolerance levels specified in table 2 to this
paragraph (d) is to be determined by measuring only pydiflumetofen (3-
(difluoromethyl)-N-methoxy-1-methyl-N-[1-methyl-2-(2,4,6-
trichlorophenyl)ethyl]-1H-pyrazole-4-carboxamide) in or on the
commodity:

                        Table 2 to Paragraph (d)
------------------------------------------------------------------------
                                                             Parts per
                        Commodity                             million
------------------------------------------------------------------------
Animal feed, nongrass, group 18, hay....................            0.04
Grass, forage, fodder and hay, group 17, except straw...             0.7
Grass, forage, fodder and hay, group 17, straw..........            0.04
------------------------------------------------------------------------

[FR Doc. 2020-17791 Filed 9-3-20; 8:45 am]
BILLING CODE 6560-50-P


Lydia Wegman/RTP/USEPA/US

05/16/2008 07:10 PM

To

"King, Heidi R."<EMAIL_ADDRESS>Deirdre Murphy/RTP/USEPA/US@EPA, Karen Martin/RTP/USEPA/US@EPA, Marion Hoyer/AA/USEPA/US@EPA, "Glenn Passavant" <EMAIL_ADDRESS>"David Orlin" <EMAIL_ADDRESS> cc

"Tricia Crabtree"<EMAIL_ADDRESS> Subject

Re: Lydia: Interagency follow up to yesterday's AvGas/Airport memo interagency mtg

Thanks for letting me know Heidi.  We need to get the memo into the docket by Tuesday, as I noted yesterday.  Do we need to meet Monday to discuss these issues?

 ----- Original Message -----

  From: "King, Heidi R."<EMAIL_ADDRESS>   Sent: 05/16/2008 06:16 PM AST

  To: Lydia Wegman; Deirdre Murphy; Karen Martin

  Subject: Lydia: Interagency follow up to yesterday's AvGas/Airport memo interagency mtg

Hi Lydia,

A couple of agencies did get back to me as follow up to yesterday’s conversation on the OTAQ memo estimating Pb emissions at the airport level.

There seems to be a disconnect on whether and how the airport-level information will be used.  Some folks have noted that OTAQ represented this analysis as *not* to be used in a regulatory process.  It sounds as if the estimates rely heavily on a couple of key assumptions, and while the estimates are believed to be better than estimates previously available, they apparently remain quite course and not necessarily sufficient to support the identification of Air Quality Monitoring equipment.

Other folks would like to learn more about the methodology.

I will reach out to you Monday morning to identify next steps,

heidi


[Federal Register Volume 83, Number 247 (Thursday, December 27, 2018)]
[Notices]
[Page 66836]
[FR Doc No: 2018-28100]

-----------------------------------------------------------------------

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

[Summary Notice No. 2018-92]

Petition for Exemption; Summary of Petition Received; The Boeing
Company

AGENCY: Federal Aviation Administration (FAA), Department of
Transportation (DOT).

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This notice contains a summary of a petition seeking relief
from specified requirements of Federal Aviation Regulations. The
purpose of this notice is to improve the public's awareness of, and
participation in, the FAA's exemption process. Neither publication of
this notice nor the inclusion or omission of information in the summary
is intended to affect the legal status of the petition or its final
disposition.

DATES: Comments on this petition must identify the petition docket
number and must be received on or before January 16, 2019.

ADDRESSES: Send comments identified by docket number FAA-2018-0839
using any of the following methods:
     Federal eRulemaking Portal: Go to http://www.regulations.gov and follow the online instructions for sending your
comments electronically.
     Mail: Send comments to Docket Operations, M-30; U.S.
Department of Transportation, 1200 New Jersey Avenue SE, Room W12-140,
West Building Ground Floor, Washington, DC 20590-0001.
     Hand Delivery or Courier: Take comments to Docket
Operations in Room W12-140 of the West Building Ground Floor at 1200
New Jersey Avenue SE, Washington, DC 20590-0001, between 9 a.m. and 5
p.m., Monday through Friday, except Federal holidays.
     Fax: Fax comments to Docket Operations at<PHONE_NUMBER>.
    Privacy: In accordance with 5 U.S.C. 553(c), DOT solicits comments
from the public to better inform its rulemaking process. DOT posts
these comments, without edit, including any personal information the
commenter provides, to http://www.regulations.gov, as described in the
system of records notice (DOT/ALL-14 FDMS), which can be reviewed at
http://www.dot.gov/privacy.
    Docket: Background documents or comments received may be read at
http://www.regulations.gov at any time. Follow the online instructions
for accessing the docket or go to the Docket Operations in Room W12-140
of the West Building Ground Floor at 1200 New Jersey Avenue SE,
Washington, DC 20590-0001, between 9 a.m. and 5 p.m., Monday through
Friday, except Federal holidays.

FOR FURTHER INFORMATION CONTACT: Keira Jones<PHONE_NUMBER>, Office of
Rulemaking, Federal Aviation Administration, 800 Independence Avenue
SW, Washington, DC 20591.
    This notice is published pursuant to 14 CFR 11.85.

    Issued in Washington, DC, on December 19, 2018.
Brandon Roberts,
Deputy Executive Director, Office of Rulemaking.

Petition for Exemption

    Docket No.: FAA-2018-0839.
    Petitioner: The Boeing Company.
    Section(s) of 14 CFR Affected: Sec. Sec.  21.191(a) and (b).
    Description of Relief Sought: The Boeing Company (Boeing) petitions
for the purposes of Exemption from Sec. Sec.  21.191(a) & (b) to allow
Boeing to conduct and accept production flight test aspects while
operating under experimental purpose. The production flight test
profile upon successful completion is accepted by the Boeing
engineering test pilot in command if the test conditions are satisfied.

[FR Doc. 2018-28100 Filed 12-26-18; 8:45 am]
BILLING CODE 4910-13-P


[Federal Register Volume 79, Number 102 (Wednesday, May 28, 2014)]
[Notices]
[Page 30603]
[FR Doc No: 2014-12326]

=======================================================================
-----------------------------------------------------------------------

ENVIRONMENTAL PROTECTION AGENCY

[EPA-HQ-OPPT-2012-0916; FRL-9911-29-OEI]

Information Collection Request Submitted to OMB for Review and
Approval; Comment Request; Asbestos-Containing Materials in Schools
Rule and Revised Asbestos Model Accreditation Plan Rule (Renewal)

AGENCY: Environmental Protection Agency (EPA).

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: EPA has submitted the following information collection request
(ICR) to the Office of Management and Budget (OMB) for review and
approval in accordance with the Paperwork Reduction Act (44 U.S.C. 3501
et seq.): Asbestos-Containing Materials in Schools Rule and Revised
Asbestos Model Accreditation Plan Rule (EPA ICR No. 1365.10, OMB
Control No. 2070-0091). EPA did not receive any comments in response to
the previously provided public review opportunity issued in the Federal
Register on August 8, 2013 (78 FR 48431). With this submission, EPA is
providing an additional 30 days for public comments. An Agency may not
conduct or sponsor and a person is not required to respond to a
collection of information unless it displays a currently valid OMB
control number.

DATES: Submit your comments on or before June 27, 2014.

ADDRESSES: Submit your comments, referencing Docket ID Number EPA-HQ-
OPPT-2012-0916, to (1) EPA online using http://www.regulations.gov (our
preferred method), by email to<EMAIL_ADDRESS>or by mail to: EPA
Docket Center, Environmental Protection Agency, Mail Code 28221T, 1200
Pennsylvania Ave. NW., Washington, DC 20460, and (2) OMB via email to
<EMAIL_ADDRESS>Address comments to the OMB Desk Officer
for EPA.
    EPA's policy is that all comments received will be included in the
public docket without change including any personal information
provided, unless the comment includes profanity, threats, information
claimed to be Confidential Business Information (CBI) or other
information whose disclosure is restricted by statute.

FOR FURTHER INFORMATION CONTACT: Pamela Myrick, Deputy Director,
Environmental Assistance Division (7408M), Office of Pollution
Prevention and Toxics, Environmental Protection Agency, 1200
Pennsylvania Ave. NW., Washington, DC 20460; telephone number: 202-554-
1404; fax number:<PHONE_NUMBER>; email address<EMAIL_ADDRESS>
SUPPLEMENTARY INFORMATION:
    Docket: The ICR, which explains in detail the information
collection activities and the related burden and cost estimates, is
summarized in this document and is available in the docket for this ICR
Renewal. The docket can be viewed online at http://www.regulations.gov
or in person at the EPA Docket Center, EPA West, Room 3334, 1301
Constitution Ave. NW., Washington, DC. The telephone number for the
Docket Center is<PHONE_NUMBER>. For additional information about EPA's
docket, visit http://www.epa.gov/dockets.
    ICR Title: Asbestos-Containing Materials in Schools Rule and
Revised Asbestos Model Accreditation Plan Rule.
    ICR numbers: EPA ICR No. 1365.10, OMB Control No. 2070-0091.
    ICR status: The current OMB approval for this ICR is scheduled to
expire on May 31, 2014. Under OMB regulations, the Agency may continue
to conduct or sponsor the collection of information while this
submission is pending at OMB.
    Abstract: The Asbestos Hazard Emergency Response Act (AHERA)
requires local education agencies (LEAs) to conduct inspections,
develop management plans, and design or conduct response actions with
respect to the presence of asbestos-containing materials in school
buildings. AHERA also requires states to develop model accreditation
plans for persons who perform asbestos inspections, develop management
control plans, and design or conduct response actions. This information
collection addresses the burden associated with recordkeeping
requirements imposed on LEAs by the asbestos in schools rule, and
reporting and recordkeeping requirements imposed on states and training
providers related to the model accreditation plan (MAP) rule.
    EPA will disclose information that is covered by a claim of
confidentiality only to the extent permitted by, and in accordance
with, the procedures in TSCA and 40 CFR part 2.
    Form numbers: None.
    Respondents/affected entities: Local education agencies (LEAs,
e.g., elementary or secondary public school districts or a private
school or school system); asbestos training providers to schools and
educational systems; state education departments or commissions; or
state public health departments or commissions.
    Respondent's obligation to respond: Mandatory (see 40 CFR parts
763, Subpart E).
    Estimated number of respondents: 133,507 (total).
    Frequency of response: On occasion.
    Total estimated burden: 2,487,439 hours per year. Burden is defined
at 5 CFR 1320.03(b).
    Total estimated cost: $91,829,253 per year, includes $0 annualized
capital or operation and maintenance costs.
    Changes in the estimates: There is a decrease of 105,449 hours in
the total estimated respondent burden compared with that identified in
the ICR currently approved by OMB. This decrease reflects EPA's reduced
estimate of the number of schools containing friable asbestos-
containing materials.

    Dated: May 16, 2014.
Erin Collard,
Acting Director, Collection Strategies Division.
[FR Doc. 2014-12326 Filed 5-27-14; 8:45 am]
BILLING CODE 6560-50-P


[Federal Register Volume 79, Number 173 (Monday, September 8, 2014)]
[Rules and Regulations]
[Pages 53134-53138]
[FR Doc No: 2014-20325]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Parts 520, 522, and 558

[Docket No. FDA-2014-N-0002]

New Animal Drugs; Buprenorphine; Carprofen; Danofloxacin;
Follicle Stimulating Hormone; Ractopamine; Salinomycin; Tylosin

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule; technical amendment.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is amending the animal
drug regulations to reflect approval actions for new animal drug
applications (NADAs) and abbreviated new animal drug applications
(ANADAs) during July 2014. FDA is also informing the public of the
availability of summaries of the basis of approval and of environmental
review documents, where applicable. The animal drug regulations are
also being amended to add a cross reference to a tolerance.

DATES: This rule is effective September 8, 2014.

FOR FURTHER INFORMATION CONTACT: George K. Haibel, Center for
Veterinary Medicine (HFV-6), Food and Drug Administration, 7519
Standish Pl., Rockville, MD 20855,<PHONE_NUMBER>,
<EMAIL_ADDRESS>
SUPPLEMENTARY INFORMATION: FDA is amending the animal drug regulations
to reflect approval actions for NADAs and ANADAs during July 2014, as
listed in table 1. In addition, FDA is informing the public of the
availability, where applicable, of documentation of environmental
review required under the National Environmental Policy Act (NEPA) and,
for actions requiring review of safety or effectiveness data, summaries
of the basis of approval (FOI Summaries) under the Freedom of
Information Act (FOIA). These public documents may be seen in the
Division of Dockets Management (HFA-305), Food and Drug Administration,
5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, between 9 a.m. and 4
p.m., Monday through Friday. Persons with access to the Internet may
obtain these documents at the Center for Veterinary Medicine (CVM) FOIA
Electronic Reading Room: http://www.fda.gov/AboutFDA/CentersOffices/OfficeofFoods/CVM/CVMFOIAElectronicReadingRoom/default.htm. Marketing
exclusivity and patent information may be accessed in FDA's
publication, Approved Animal Drug Products Online (Green Book) at:
http://www.fda.gov/AnimalVeterinary/Products/ApprovedAnimalDrugProducts/default.htm.
    Also, the animal drug regulations are being amended in 21 CFR
522.955 to add a cross reference to a tolerance for an inactive vehicle
in an injectable dosage form product. This amendment is being made to
improve the accuracy of the regulations.
    This rule does not meet the definition of ``rule'' in 5 U.S.C.
804(3)(A) because it is a rule of ``particular applicability.''
Therefore, it is not subject to the congressional review requirements
in 5 U.S.C. 801-808.

                                      Table 1--Original and Supplemental NADAs and ANADAs Approved During July 2014
--------------------------------------------------------------------------------------------------------------------------------------------------------
                                                    New animal drug                                21 CFR
       NADA/ANADA                Sponsor              product name              Action            sections        FOIA summary          NEPA  review
--------------------------------------------------------------------------------------------------------------------------------------------------------
013-076 \1\............  Elanco Animal Health,   TYLAN (tylosin         Supplemental approval        520.2640  yes...............  EA/FONSI \2\
                          A Division of Eli       tartrate) Soluble      for the control of
                          Lilly & Co., Lilly      Powder.                mortality caused by
                          Corporate Center,                              necrotic enteritis
                          Indianapolis, IN                               associated with
                          46285.                                         Clostridium
                                                                         perfringens in
                                                                         broiler chickens.
141-207................  Zoetis Inc., 333        ADVOCIN (danofloxacin  Supplemental approval         522.522  yes...............  CE \3\ \4\
                          Portage St.,            injection) Sterile     for control of
                          Kalamazoo, MI 49007.    Injectable Solution.   bovine respiratory
                                                                         disease (BRD) in
                                                                         beef cattle at high
                                                                         risk of developing
                                                                         BRD associated with
                                                                         Mannheimia
                                                                         haemolytica and
                                                                         Pasteurella
                                                                         multocida.
141-431................  Bioniche Animal Health  FOLLTROPIN (porcine    Original approval for        522.1002  yes...............  CE \3\ \5\
                          USA, Inc., 119 Rowe     pituitary-derived      the induction of
                          Rd., Athens, GA 30601.  follicle stimulating   superovulation in
                                                  hormone for            beef and dairy
                                                  injection).            heifers and cows.
141-434................  Abbott Laboratories,    SIMBADOL               Original approval for         522.230  yes...............  CE \3\ \6\
                          North Chicago, IL       (buprenorphine         control of
                          60064.                  injection).            postoperative pain
                                                                         associated with
                                                                         surgical procedures
                                                                         in cats.
200-520................  Norbrook Laboratories,  CARPRIEVE (carprofen)  Original approval as          522.304  yes...............  CE \3\ \7\
                          Ltd., Station Works,    Injection.             a generic copy of
                          Newry BT35 6JP,                                NADA 141-199.
                          Northern Ireland.
200-559................  Zoetis Inc., 333        ACTOGAIN 45            Original approval as          558.500  yes...............  CE \3\ \7\
                          Portage St.,            (ractopamine HCl)      a generic copy of
                          Kalamazoo, MI 49007.    plus RUMENSIN          NADA 141-225.
                                                  (monensin) Type B
                                                  and C medicated
                                                  feeds.
200-566 \1\............  Huvepharma AD, 5th      OPTAFLEXX 45           Original approval as          558.500  yes...............  CE \3\ \7\
                          Floor, 3A Nikolay       (ractopamine HCl)      a generic copy of
                          Haytov Str., 1113       plus RUMENSIN          NADA 141-224.
                          Sophia, Bulgaria.       (monensin) plus
                                                  TYLOVET (tylosin
                                                  phosphate) Type B
                                                  and C medicated
                                                  feeds.
200-567 \1\............  Huvepharma AD, 5th      OPTAFLEXX 45           Original approval as          558.500  yes...............  CE \3\ \7\
                          Floor, 3A Nikolay       (ractopamine HCl)      a generic copy of
                          Haytov Str., 1113       plus RUMENSIN          NADA 141-233.
                          Sophia, Bulgaria.       (monensin) plus
                                                  TYLOVET (tylosin
                                                  phosphate) plus MGA
                                                  (melengestrol
                                                  acetate) Type B and
                                                  C medicated feeds.
200-569 \1\............  Huvepharma AD, 5th      TYLAN (tylosin         Original approval as          558.550  yes...............  CE \3\ \7\
                          Floor, 3A Nikolay       phosphate) plus        a generic copy of
                          Haytov Str., 1113       SACOX (salinomycin     NADA 141-198.
                          Sophia, Bulgaria.       sodium) Type C
                                                  medicated feeds.
200-570 \1\............  Huvepharma AD, 5th      TYLOVET (tylosin       Original approval as          558.550  yes...............  CE \3\ \7\
                          Floor, 3A Nikolay       phosphate) plus BIO-   a generic copy of
                          Haytov Str., 1113       COX (salinomycin       NADA 141-198.
                          Sophia, Bulgaria.       sodium) Type C
                                                  medicated feeds.
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ The listed application is affected by guidance for industry (GFI) 213, ``New Animal Drugs and New Animal Drug Combination Products
  Administered in or on Medicated Feed or Drinking Water of Food-Producing Animals: Recommendations for Drug Sponsors for Voluntarily Aligning Product
  Use Conditions with GFI 209'', December 2013.
\2\ The Agency has carefully considered an environmental assessment (EA) of the potential environmental impact of this action and has made a finding of
  no significant impact (FONSI).
\3\ The Agency has determined under 21 CFR 25.33 that this action is categorically excluded (CE) from the requirement to submit an environmental
  assessment or an environmental impact statement because it is of a type that does not individually or cumulatively have a significant effect on the
  human environment.
\4\ CE granted under 21 CFR 25.33(d)(5).
\5\ CE granted under 21 CFR 25.33(c).
\6\ CE granted under 21 CFR 25.33(d)(1).
\7\ CE granted under 21 CFR 25.33(a)(1).

List of Subjects

21 CFR Parts 520 and 522

    Animal drugs.

21 CFR Part 558

    Animal drugs, Animal feeds.

    Therefore, under the Federal Food, Drug, and Cosmetic Act and under
authority delegated to the Commissioner of Food and Drugs and
redelegated to the Center for Veterinary Medicine, 21 CFR parts 520,
522, and 558 are amended as follows:

PART 520--ORAL DOSAGE FORM NEW ANIMAL DRUGS

0
1. The authority citation for 21 CFR part 520 continues to read as
follows:

    Authority: 21 U.S.C. 360b.

0
2. In Sec.  520.2640, revise paragraphs (b) and (e)(1) to read as
follows:

Sec.  520.2640  Tylosin.

* * * * *
    (b) Sponsors. (1) No. 000986 for use as in paragraphs (e)(1),
(e)(2)(i), (e)(2)(ii)(A), (e)(2)(iii), (e)(3), and (e)(4) of this
section.
    (2) No. 016592 for use as in paragraphs (e)(1)(i)(A), (e)(1)(ii),
(e)(2)(i), (e)(2)(ii)(A), (e)(2)(iii), (e)(3), and (e)(4) of this
section.
    (3) No. 061623 for use as in paragraphs (e)(1)(i)(A), (e)(1)(ii),
(e)(2)(i), (e)(2)(ii)(B), (e)(2)(iii), (e)(3), and (e)(4) of this
section.
* * * * *
    (e) * * *
    (1) Chickens--(i) Amounts and indications for use.--(A) Administer
2 grams per gallon (528 parts per million (ppm)) for 1 to 5 days as an
aid in the treatment of chronic respiratory disease (CRD) associated
with Mycoplasma gallisepticum in broiler and replacement chickens. For
the control of CRD associated with M. gallisepticum at time of
vaccination or other stress in chickens. For the control of CRD
associated with Mycoplasma synoviae in broiler chickens. Treated
chickens should consume enough medicated drinking water to provide 50
milligrams (mg) tylosin per pound of body weight per day.
    (B) Administer 851 to 1,419 mg/gallon (225 to 375 ppm) for 5 days
for the control of mortality caused by necrotic enteritis associated
with Clostridium perfringens in broiler chickens.
    (ii) Limitations. Do not use in layers producing eggs for human
consumption. Do not administer within 24 hours of slaughter.
* * * * *

PART 522--IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS

0
3. The authority citation for 21 CFR part 522 continues to read as
follows:

    Authority: 21 U.S.C. 360b.

0
4. Add Sec.  522.230 to read as follows:

Sec.  522.230  Buprenorphine.

    (a) Specifications. Each milliliter of solution contains 1.8
milligrams (mg) buprenorphine.
    (b) Sponsor. See No. 000044 in Sec.  510.600(c) of this chapter.
    (c) Conditions of use in cats--(1) Amount. Administer 0.24 mg per
kilogram (0.11 mg per pound) by subcutaneous injection once daily, for
up to 3 days. Administer the first dose approximately 1 hour prior to
surgery.
    (2) Indications for use. For the control of postoperative pain
associated with surgical procedures in cats.
    (3) Limitations. Federal law restricts this drug to use by or on
the order of a licensed veterinarian.

Sec.  522.304  [Amended]

0
5. In Sec.  522.304, paragraph (b), remove ``No. 054771'' and in its
place add ``Nos. 054771 and 055529''.

0
6. In Sec.  522.522, remove paragraph (d)(2); redesignate paragraph
(d)(3) as paragraph (d)(2); and revise paragraph (d)(1) to read as
follows:

Sec.  522.522  Danofloxacin.

* * * * *
    (d) * * *
    (1) Amount and indications for use. Administer by subcutaneous
injection either:
    (i) 6 mg per kilogram (/kg) of body weight, repeated in 48 hours,
for the treatment of bovine respiratory disease (BRD) associated with
Mannheimia haemolytica and Pasteurella multocida; or
    (ii) 8 mg/kg of body weight as a single dose for the treatment of
BRD associated with M. haemolytica and P. multocida and for the control
of BRD in beef cattle at high risk of developing BRD associated with M.
haemolytica and P. multocida.
* * * * *

0
7. In Sec.  522.955, revise paragraph (c) to read as follows:

Sec.  522.955  Florfenicol.

* * * * *
    (c) Related tolerances. See Sec. Sec.  500.1410 and 556.283 of this
chapter.
* * * * *

0
8. In Sec.  522.1002, add paragraph (c) to read as follows:

Sec.  522.1002  Follicle stimulating hormone.

* * * * *
    (c)(1) Specifications. Each package contains 2 vials. One vial
contains 700 international units (IU) porcine-pituitary derived
follicle stimulating hormone (FSH) equivalent to 400 milligrams NIH-
FSH-P1, as a dry powder. The other vial contains 20 milliliters (mL) of
bacteriostatic sodium chloride injection. When reconstituted, each
milliliter of constituted solution contains 35 IU FSH.
    (2) Sponsor. See No. 064847 in Sec.  510.600(c) of this chapter.
    (3) Conditions of use--(i) Dosage. Administer 2.5 mL (87.5 IU)
intramuscularly, twice daily at 12-hour intervals, for 4 consecutive
days. In conjunction with the 6th dose, administer an approved
prostaglandin product for cattle (cloprostenol sodium or dinoprost
tromethamine), using the labeled dosage and administration instructions
to cause luteolysis and induce estrus. See Sec.  522.460 for use of
cloprostenol sodium or Sec.  522.690 for use of dinoprost tromethamine.
    (ii) Indications for use. For the induction of superovulation in
beef and dairy heifers and cows.
    (iii) Limitations. Federal law restricts this drug to use by or on
the order of a licensed veterinarian.

PART 558--NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS

0
9. The authority citation for 21 CFR part 558 continues to read as
follows:

    Authority: 21 U.S.C. 360b, 371.

0
10. In Sec.  558.500, revise paragraphs (e)(2)(ii), (e)(2)(iv),
(e)(2)(vii), (e)(2)(ix), (e)(2)(x), (e)(2)(xii), and (e)(2)(xiii), to
read as follows:

Sec.  558.500  Ractopamine.

* * * * *
    (e) * * *
    (2) * * *

----------------------------------------------------------------------------------------------------------------
                                   Combination in    Indications for
    Ractopamine in grams/ton         grams/ton             use            Limitations             Sponsor
----------------------------------------------------------------------------------------------------------------

                                                  * * * * * * *
(ii) 8.2 to 24.6...............  Monensin 10 to 40  Cattle fed in      As in paragraph    000986, 054771
                                  to provide 0.14    confinement for    (e)(2)(i) of
                                  to 0.42 mg         slaughter: As in   this section;
                                  monensin/lb of     paragraph          see paragraph
                                  body weight,       (e)(2)(i) of       Sec.  Sec.
                                  depending on       this section;      558.355(d) of
                                  severity of        for prevention     this chapter.
                                  coccidiosis        and control of     Ractopamine as
                                  challenge, up to   coccidiosis due    provided by Nos.
                                  480 mg/head/day.   to Eimeria bovis   000986 or 054771
                                                     and E zuernii.     in Sec.
                                                                        510.600(c) of
                                                                        this chapter;
                                                                        monensin as
                                                                        provided by No.
                                                                        000986 in Sec.
                                                                        510.600(c) of
                                                                        this chapter.

                                                  * * * * * * *
(iv) 8.2 to 24.6...............  Monensin 10 to 40  Cattle fed in      As in paragraph    000986, 016592, 054771
                                  to provide 0.14    confinement for    (e)(2)(i) of
                                  to 0.42 mg         slaughter: As in   this section;
                                  monensin/lb of     paragraph          see Sec.  Sec.
                                  body weight,       (e)(2)(i) of       558.355(d) and
                                  depending on       this section;      558.625(c) of
                                  severity of        for prevention     this chapter.
                                  coccidiosis        and control of     Ractopamine as
                                  challenge, up to   coccidiosis due    provided by No.
                                  480 mg/head/day,   to Eimeria bovis   000986 with
                                  plus tylosin 8     and E zuernii;     tylosin as
                                  to 10.             and for            provided by Nos.
                                                     reduction of       000986 or 016592
                                                     incidence of       in Sec.
                                                     liver abscesses    510.600(c) of
                                                     caused by          this chapter; or
                                                     Fusobacterium      ractopamine as
                                                     necrophorum and    provided by No.
                                                     Arcanobacterium    054771 with
                                                     (Actinomyces)      tylosin as
                                                     pyogenes.          provided by No.
                                                                        000986 in Sec.
                                                                        510.600(c) of
                                                                        this chapter.

                                                  * * * * * * *
(vii) 9.8 to 24.6..............  Monensin 10 to 40  Cattle fed in      As in paragraph    000986, 054771
                                  to provide 0.14    confinement for    (e)(2)(vi) of
                                  to 0.42 mg         slaughter: As in   this section;
                                  monensin/lb of     paragraph          see paragraph
                                  body weight,       (e)(2)(vi) of      Sec.  Sec.
                                  depending on       this section;      558.355(d) of
                                  severity of        for prevention     this chapter.
                                  coccidiosis        and control of     Ractopamine as
                                  challenge, up to   coccidiosis due    provided by Nos.
                                  480 mg/head/day.   to Eimeria bovis   000986 or 054771
                                                     and E zuernii.     in Sec.
                                                                        510.600(c) of
                                                                        this chapter;
                                                                        monensin as
                                                                        provided by No.
                                                                        000986 in Sec.
                                                                        510.600(c) of
                                                                        this chapter.

                                                  * * * * * * *
(ix) 9.8 to 24.6...............  Monensin 10 to 40  Cattle fed in      As in paragraph    000986, 016592, 054771
                                  to provide 0.14    confinement for    (e)(2)(vi) of
                                  to 0.42 mg         slaughter: As in   this section;
                                  monensin/lb of     paragraph          see Sec.  Sec.
                                  body weight,       (e)(2)(vi) of      558.355(d) and
                                  depending on       this section;      558.625(c) of
                                  severity of        for prevention     this chapter.
                                  coccidiosis        and control of     Ractopamine and
                                  challenge, up to   coccidiosis due    monensin as
                                  480 mg/head/day,   to Eimeria bovis   provided by No.
                                  plus tylosin 8     and E zuernii;     000986 with
                                  to 10.             and for            tylosin as
                                                     reduction of       provided by Nos.
                                                     incidence of       000986 or 016592
                                                     liver abscesses    in Sec.
                                                     caused by          510.600(c) of
                                                     Fusobacterium      this chapter; or
                                                     necrophorum and    ractopamine as
                                                     Arcanobacterium    provided by No.
                                                     (Actinomyces)      054771 with
                                                     pyogenes.          monensin and
                                                                        tylosin as
                                                                        provided by No.
                                                                        000986 in Sec.
                                                                        510.600(c) of
                                                                        this chapter.

(x) 9.8 to 24.6................  Monensin 10 to 40  Heifers fed in     As in paragraph    000986, 016592, 054771
                                  to provide 0.14    confinement for    (e)(2)(vi) of
                                  to 0.42 mg         slaughter: As in   this section;
                                  monensin/lb of     paragraph          see paragraphs
                                  body weight,       (e)(2)(vi) of      Sec.  Sec.
                                  depending on       this section;      558.342(d),
                                  severity of        for prevention     558.355(d) and
                                  coccidiosis        and control of     558.625(c) of
                                  challenge, up to   coccidiosis due    this chapter.
                                  480 mg/head/day,   to Eimeria bovis   Ractopamine,
                                  plus tylosin 8     and E zuernii;     monensin, and
                                  to 10, plus        for reduction of   tylosin as
                                  melengestrol       incidence of       provided by No.
                                  acetate to         liver abscesses    000986 with
                                  provide 0.25 to    caused by          melengestrol
                                  0.5 mg/head/day.   Fusobacterium      acetate as
                                                     necrophorum and    provided by Nos.
                                                     Arcanobacterium    000986 or 054771
                                                     (Actinomyces)      in Sec.
                                                     pyogenes; and      510.600(c) of
                                                     for suppression    this chapter; or
                                                     of estrus (heat).  ractopamine and
                                                                        monensin as
                                                                        provided by No.
                                                                        000986 with
                                                                        tylosin as
                                                                        provided by Nos.
                                                                        000986 or 016592
                                                                        and melengestrol
                                                                        acetate as
                                                                        provided by No.
                                                                        054771 in Sec.
                                                                        510.600(c) of
                                                                        this chapter; or
                                                                        ractopamine as
                                                                        provided by No.
                                                                        054771 with
                                                                        monensin and
                                                                        tylosin as
                                                                        provided by No.
                                                                        000986 and
                                                                        melengestrol
                                                                        acetate provided
                                                                        by No. 054771 in
                                                                        Sec.
                                                                        510.600(c) of
                                                                        this chapter.

                                                  * * * * * * *
(xii) Not to exceed 800; to      Monensin 10 to 40  Cattle fed in      Top dress          000986, 054771
 provide 70 to 400 mg/head/day.   to provide 0.14    confinement for    ractopamine in a
                                  to 0.42 mg         slaughter: As in   minimum of 1.0
                                  monensin/lb of     paragraph          lb of medicated
                                  body weight,       (e)(2)(i) of       feed during the
                                  depending on       this section;      last 28 to 42
                                  severity of        for prevention     days on feed.
                                  coccidiosis        and control of     Not for animals
                                  challenge, up to   coccidiosis due    intended for
                                  480 mg/head/day.   to Eimeria bovis   breeding. See
                                                     and E zuernii.     Sec.
                                                                        558.355(d).
                                                                        Ractopamine as
                                                                        provided by Nos.
                                                                        000986 or 054771
                                                                        in Sec.
                                                                        510.600(c) of
                                                                        this chapter;
                                                                        monensin as
                                                                        provided by No.
                                                                        000986 in Sec.
                                                                        510.600(c) of
                                                                        this chapter.
(xiii) Not to exceed 800; to     Monensin 10 to 40  Cattle fed in      Top dress          000986, 016592, 054771
 provide 70 to 400 mg/head/day.   to provide 0.14    confinement for    ractopamine in a
                                  to 0.42 mg         slaughter: As in   minimum of 1.0
                                  monensin/lb of     paragraph          lb of medicated
                                  body weight,       (e)(2)(i) of       feed during the
                                  depending on       this section;      last 28 to 42
                                  severity of        for prevention     days on feed.
                                  coccidiosis        and control of     Not for animals
                                  challenge, up to   coccidiosis due    intended for
                                  480 mg/head/day,   to Eimeria bovis   breeding. See
                                  plus tylosin 8     and E zuernii;     Sec.  Sec.
                                  to 10.             and for            558.355(d) and
                                                     reduction of       558.625(c).
                                                     incidence of       Ractopamine and
                                                     liver abscesses    monensin as
                                                     caused by          provided by No.
                                                     Fusobacterium      000986 with
                                                     necrophorum and    tylosin as
                                                     Arcanobacterium    provided by Nos.
                                                     (Actinomyces)      000986 or 016592
                                                     pyogenes.          in Sec.
                                                                        510.600(c) of
                                                                        this chapter; or
                                                                        ractopamine as
                                                                        provided by No.
                                                                        054771 with
                                                                        monensin and
                                                                        tylosin as
                                                                        provided by No.
                                                                        000986 in Sec.
                                                                        510.600(c) of
                                                                        this chapter.
----------------------------------------------------------------------------------------------------------------

* * * * *

0
11. In Sec.  558.550, revise the last sentence in paragraph
(d)(1)(xxii)(B) to read as follows:

Sec.  558.550  Salinomycin.

* * * * *
    (d) * * *
    (1) * * *
    (xxii) * * *
    (B) * * * Salinomycin as provided by Nos. 016592 and 054771;
tylosin phosphate as provided by Nos. 000986 and 016592 in Sec.
510.600(c) of this chapter.
* * * * *

    Dated: August 21, 2014.
Bernadette Dunham,
Director, Center for Veterinary Medicine.
[FR Doc. 2014-20325 Filed 9-5-14; 8:45 am]
BILLING CODE 4164-01-P


[Federal Register Volume 86, Number 42 (Friday, March 5, 2021)]
[Proposed Rules]
[Pages 12866-12868]
[FR Doc No: 2021-03970]

-----------------------------------------------------------------------

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

14 CFR Part 71

[Docket No. FAA-2021-0062; Airspace Docket No. 20-ASO-21]
RIN 2120-AA66

Proposed Amendment of Area Navigation (RNAV) Route T-207; in the
Vicinity of Cecil, FL

AGENCY: Federal Aviation Administration (FAA), DOT.

ACTION: Notice of proposed rulemaking (NPRM).

-----------------------------------------------------------------------

SUMMARY: This action proposes to amend low altitude RNAV route T-207 in
Florida. The proposed change would remove the Cecil, FL (VQQ), VOR from
the route description due to the planned decommissioning of that VOR.
The removal would not affect navigation along the route.

DATES: Comments must be received on or before April 19, 2021.

ADDRESSES: Send comments on this proposal to the U.S. Department of
Transportation, Docket Operations, 1200 New Jersey Avenue SE, West
Building Ground Floor, Room W12-140, Washington, DC 20590; telephone: 1
(800) 647-5527 or<PHONE_NUMBER>. You must identify FAA Docket No. FAA-
2021-0062; Airspace Docket No. 20-ASO-21 at the beginning of your
comments. You may also submit comments through the internet at https://www.regulations.gov. FAA Order 7400.11E, Airspace Designations and
Reporting Points, and subsequent amendments can be viewed online at
https://www.faa.gov/air_traffic/publications/. For further information,
you can contact the Policy Group, Federal Aviation Administration, 800
Independence Avenue SW, Washington, DC 20591; telephone: (202) 267-
8783. The Order is also available for inspection at the National
Archives and Records Administration (NARA). For information on the
availability of FAA Order 7400.11E at NARA, email:
<EMAIL_ADDRESS>or go to https://www.archives.gov/federal-register/cfr/ibr-locations.html.

FOR FURTHER INFORMATION CONTACT: Paul Gallant, Rules and Regulations
Group, Office of Policy, Federal Aviation Administration, 800
Independence Avenue SW, Washington, DC 20591; telephone: (202) 267-
8783.

SUPPLEMENTARY INFORMATION:

Authority for This Rulemaking

    The FAA's authority to issue rules regarding aviation safety is
found in Title 49 of the United States Code. Subtitle I, Section 106
describes the authority of the FAA Administrator. Subtitle VII,
Aviation Programs, describes in more detail the scope of the agency's
authority. This rulemaking is promulgated under the authority described
in Subtitle VII, Part A, Subpart I, Section 40103. Under that section,
the FAA is charged with prescribing regulations to assign the use of
the airspace necessary to ensure the safety of aircraft and the
efficient use of airspace. This regulation is within the scope of that
authority as it would expand the availability of RNAV in the
southeastern United States to improve

the efficiency of the National Airspace System by lessening the
dependency on ground-based navigation aids.

Comments Invited

    Interested parties are invited to participate in this proposed
rulemaking by submitting such written data, views, or arguments as they
may desire. Comments that provide the factual basis supporting the
views and suggestions presented are particularly helpful in developing
reasoned regulatory decisions on the proposal. Comments are
specifically invited on the overall regulatory, aeronautical, economic,
environmental, and energy-related aspects of the proposal.
    Communications should identify both docket numbers (FAA Docket No.
FAA-2021-0062; Airspace Docket No. 20-ASO-21 and be submitted in
triplicate to the Docket Management Facility (see ADDRESSES section for
address and phone number). You may also submit comments through the
internet at https://www.regulations.gov.
    Commenters wishing the FAA to acknowledge receipt of their comments
on this action must submit with those comments a self-addressed,
stamped postcard on which the following statement is made: ``Comments
to FAA Docket No. FAA-2021-0062; Airspace Docket No. 20-ASO-21.'' The
postcard will be date/time stamped and returned to the commenter.
    All communications received on or before the specified comment
closing date will be considered before taking action on the proposed
rule. The proposal contained in this action may be changed in light of
comments received. A report summarizing each substantive public contact
with FAA personnel concerned with this rulemaking will be filed in the
docket.

Availability of NPRM's

    An electronic copy of this document may be downloaded through the
internet at https://www.regulations.gov. Recently published rulemaking
documents can also be accessed through the FAA's web page at https://www.faa.gov/air_traffic/publications/airspace_amendments/.
    You may review the public docket containing the proposal, any
comments received and any final disposition in person in the Dockets
Office (see ADDRESSES section for address and phone number) between
9:00 a.m. and 5:00 p.m., Monday through Friday, except federal
holidays. An informal docket may also be examined during normal
business hours at the office of the Eastern Service Center, Federal
Aviation Administration, Room 210, 1701 Columbia Ave., College Park, GA
30337.

Availability and Summary of Documents for Incorporation by Reference

    This document proposes to amend FAA Order 7400.11E, Airspace
Designations and Reporting Points, dated July 21, 2020, and effective
September 15, 2020. FAA Order 7400.11E is publicly available as listed
in the ADDRESSES section of this proposed rule. FAA Order 7400.11E
lists Class A, B, C, D, and E airspace areas, air traffic service
routes, and reporting points.

The Proposal

    The FAA is proposing an amendment to 14 CFR part 71 to amend low
altitude RNAV route T-207 by removing the Cecil, FL (VQQ), VOR from the
route description. This action is necessary due to the planned
decommissioning of the Cecil VOR. T-207 currently extends between the
Ormond Beach, FL (OMN), VORTAC, and the Waycross, GA (AYS), VORTAC. The
Cecil VOR is located along a straight segment of the route between the
CARRA, FL, Fix, and the MONIA, FL, Fix. The VOR is not a required
component for navigating on T-207. Removal of the Cecil VOR would not
affect the alignment or navigation along T-207.
    In addition, all latitude/longitude coordinates in the route
description would be updated to the hundredths of a second place for
greater navigation accuracy.
    United States Area Navigation routes are published in paragraph
6011 of FAA Order 7400.11E, dated July, 21, 2020, and effective
September 15, 2020, which is incorporated by reference in 14 CFR 71.1.
The RNAV route listed in this document would be subsequently published
in the Order.
    FAA Order 7400.11, Airspace Designations and Reporting Points, is
published yearly and effective on September 15.

Regulatory Notices and Analyses

    The FAA has determined that this proposed regulation only involves
an established body of technical regulations for which frequent and
routine amendments are necessary to keep them operationally current.
It, therefore: (1) Is not a ``significant regulatory action'' under
Executive Order 12866; (2) is not a ``significant rule'' under
Department of Transportation (DOT) Regulatory Policies and Procedures
(44 FR 11034; February 26, 1979); and (3) does not warrant preparation
of a regulatory evaluation as the anticipated impact is so minimal.
Since this is a routine matter that will only affect air traffic
procedures and air navigation, it is certified that this proposed rule,
when promulgated, will not have a significant economic impact on a
substantial number of small entities under the criteria of the
Regulatory Flexibility Act.

Environmental Review

    This proposal will be subject to an environmental analysis in
accordance with FAA Order 1050.1F, ``Environmental Impacts: Policies
and Procedures'' prior to any FAA final regulatory action.

List of Subjects in 14 CFR Part 71

    Airspace, Incorporation by reference, Navigation (air).

The Proposed Amendment

    In consideration of the foregoing, the Federal Aviation
Administration proposes to amend 14 CFR part 71 as follows:

PART 71--DESIGNATION OF CLASS A, B, C, D, AND E AIRSPACE AREAS; AIR
TRAFFIC SERVICE ROUTES; AND REPORTING POINTS

0
1. The authority citation for part 71 continues to read as follows:

    Authority:  49 U.S.C. 106(f), 106(g); 40103, 40113, 40120; E.O.
10854, 24 FR 9565, 3 CFR, 1959-1963 Comp., p. 389.

Sec.  71.1   [Amended]

0
2. The incorporation by reference in 14 CFR 71.1 of FAA Order 7400.11E,
Airspace Designations and Reporting Points, dated July 21, 2020, and
effective September 15, 2020, is amended as follows:

Paragraph 6011 United States Area Navigation Routes

* * * * *

T-207 Ormond Beach, (OMN) to Waycross, GA (AYS) [Amended]
Ormond Beach, FL (OMN)                          VORTAC                         (Lat. 29[deg]18'11.71'' N, long. 81[deg]06'45.71'' W)
CARRA, FL                                       Fix                            (Lat. 29[deg]43'50.91'' N, long. 81[deg]36'29.10'' W)
MONIA, FL                                       Fix                            (Lat. 30[deg]28'49.00'' N, long. 82[deg]02'53.44'' W)
Waycross, GA (AYS)                              VORTAC                         (Lat. 31[deg]16'09.93'' N, long. 82[deg]33'23.20'' W)

* * * * *

    Issued in Washington, DC, on February 22, 202.
George Gonzalez,
Acting Manager, Rules and Regulations Group.
[FR Doc. 2021-03970 Filed 3-4-21; 8:45 am]
BILLING CODE 4910-13-P